A trial of cabazitaxel for liposarcoma (EORTC-1202)
Cancer type:
Status:
Phase:
This trial looked at cabazitaxel for liposarcoma that had spread to other parts of the body. Or it wasn’t possible to remove the sarcoma with surgery. This is advanced liposarcoma.
The trial was open for people to join between 2017 and 2019. The team presented the results at a conference in 2020.
More about this trial
is a type of soft tissue sarcoma. Doctors often treat liposarcoma with chemotherapy. When this trial was done, they may have used drugs such as doxorubicin and ifosfamide. But sometimes they didn’t work very well. So doctors wanted to improve treatment.
In this trial they looked at a chemotherapy drug called cabazitaxel.
The main aims of the trial were to find out:
- if cabazitaxel can stop advanced liposarcoma from getting worse
- more about the side effects
Summary of results
The trial team found that cabazitaxel helped stop the liposarcoma from growing again for a short time in some people. They also found that the side effects were acceptable.
Trial design
This was a phase 2 trial. It took place worldwide. 38 people were suitable to have treatment as part of this trial.
Everyone taking part had cabazitaxel. They had it for as long as it was working and for as long as the side effects weren’t too bad.
Results
After about 12 weeks, the team looked at the number of people living whose cancer hadn’t started to grow again. They found this was 21 out of 38 people (55%).
They also looked at how well treatment worked. They found the cancer:
- went away completely in one person
- shrunk a bit in 2 people
- stayed the same in 23 people
- got worse in 12 people
The team followed everyone up for about 22 months. They looked at how long it was before the cancer started to grow again. Half the people’s cancer got worse 6 months after joining the trial. They also looked at how long people lived. Half the people were living 21 months after joining the trial.
These results are similar to having the standard chemotherapy available when the trial was done. The trial team say that further research that compares cabazitaxel to standard chemotherapy needs to be done to confirm the results.
Side effects
The trial team looked at the severe side effects of cabazitaxel. The most common included:
- an increased risk of infection
- a temperature and a drop in a type of white blood cell called
neutrophils - an increased risk of tiredness and breathlessness (
anaemia)
Conclusion
The trial team concluded that the results from this small trial are encouraging. Cabazitaxel worked for some people with advanced liposarcoma to slow the cancer growth for a short time.
These findings suggest that it should be looked at in a larger . This is to see how well it works when compared to standard chemotherapy for liposarcoma.
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists () but may not have been published in a medical journal. The figures we quote above were provided by the research team. We have not analysed the data ourselves.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Richard L Hayward
Supported by
European Organisation for Research and treatment of cancer (EORTC)
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Sanofi
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
